Tolerx, Inc.

Tolerx, Inc.

Founded 2000

Cambridge, United States 9 employees Venture round Total: $145.50M Biotechnology, Health Care

Tolerx, Inc. is a trailblazer in immunology, with a remarkable array of pioneering drug candidates designed to combat not only type 1 diabetes, but also a range of autoimmune disorders and cancer by restoring balance to immune responses. The company's lineup features otelixizumab, its primary candidate in Phase 3 development to address type 1 diabetes, developed in collaboration with GlaxoSmithKline. Additionally, TRX518, a targeted T cell immunotherapy for cancer, is advancing through Phase 1 trials. The company's repertoire also includes TRX1, an anti-CD4 antibody that has undergone clinical assessment for addressing abnormal immune responses. Towards this end, the company is also exploring two preclinical candidates, TRX585 and TRX385, which aim to enhance immune responses and hold potential in treating cancer and chronic viral infections. Founded in 2000, the company is based in Cambridge, MA, USA. As of December 1, 2010, it secured a $1.50M Venture Round investment. Tolerx, Inc. remains a privately held establishment that continues to chart new paths in the domain of Biotechnology and Health Care.

Funding Stage	Amount	Investors	Lead Investors	Date
Venture Round	$1.50M	-		01 Dec 2010
Series D	$61.00M	10	Skyline Ventures, HealthCare Ventures +8	21 Oct 2006
Series D	$31.00M	-		29 Mar 2005
Series C	$35.00M	-		10 Jan 2003
Series B	$17.00M	-		24 Oct 2001

Funding Stage

Amount

Investors

Lead Investors

Date

Venture Round

$1.50M

01 Dec 2010

Series D

$61.00M

Skyline Ventures, HealthCare Ventures +8

21 Oct 2006

Series D

$31.00M

29 Mar 2005

Series C

$35.00M

10 Jan 2003

Series B

$17.00M

24 Oct 2001

FAQ About Tolerx, Inc.

Tolerx, Inc., a world leader in immunology, has a portfolio of innovative, first-in-class drug candidates to treat type 1 diabetes, other autoimmune diseases, and cancer by normalizing immune responses. The company’s pipeline includes its lead candidate, otelixizumab, a targeted T cell immunotherapy...

Tolerx, Inc. was founded in 2000.

Tolerx, Inc. is headquartered in Cambridge, United States.

Tolerx, Inc. operates in Biotechnology and Health Care. Its work centres on cancer treatment, diabetes treatment, autoimmune disease and immunotherapy.

Tolerx, Inc. has approximately 9 employees.

Tolerx, Inc. has completed 5 funding rounds, raising a total of $145.50M. The latest funding stage is Venture round.

Top alternatives and competitors to Tolerx, Inc. include Novelogics Biotechnology Inc., ImmunoCellular Therapeutics Ltd, VBL Therapeutics (Nasdaq:VBLT), Q32 Bio Inc., Coley Pharmaceutical Group. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Tolerx, Inc. and Novelogics Biotechnology Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Tolerx, Inc.

Funding Rounds & Investors (5)

Tolerx, Inc. Alternatives & Competitors

FAQ About Tolerx, Inc.